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the proton pump inhibitor omeprazole is administered to dogs with gastroduodenal ulceration or 
ǡǦͷ
antiemetic drug. in people, omeprazole is overprescribed in hospitals, increasing the risk of adverse 
ơǤ
maropitant in our veterinary specialist hospital, we conducted a prospective observational study in 
its Medicine and Surgery wards, recording patient data and obtaining contemporaneous information 
ǤǡƤ
and maropitant are administered to a large proportion of dogs, including to many of those with no 
ǤƤ
ƤǤƤ
predictors of administration of both drugs vary according to clinical setting but that these modalities 
yield concordant results. Reviewing the manner of administration and stated indications for use 
ǡƤǡ
both drugs are frequently administered for aims that are unlikely to be achieved when considering 
ơǤǡ
omeprazole and maropitant citrate in hospitalised dogs, highlighting a need for initiatives to decrease 
inappropriate prescribing.
Gastroprotectant (GP) drugs, including the proton pump inhibitor (PPI) omeprazole, increase the pH of gastric 
!uid, facilitating repair of damaged tissue in the stomach and proximal small intestine. Consequently, omeprazole 
is indicated in dogs for treatment of gastroduodenal ulceration, which may be caused by locally invasive neopla-
sia, hepatic disease, in!ammatory bowel disease, ingestion of non-steroidal anti-in!ammatory drugs (NSAIDs), 
or hyperstimulation of gastric acid production by  gastrinomas1–3. Omeprazole is also indicated for treatment 
of oesophagitis, which is frequently caused or exacerbated by re!ux of acidic gastric !uid into the  oesophagus4. 
Similarly, pre-operative administration of omeprazole decreases the frequency of oesophageal low pH events 
caused by gastro-oesophageal re!ux (GOR)5; this is probably because PPIs increase the pH of gastric !uid rather 
than because they decrease the frequency of re!ux  events6. However, it remains unclear whether prophylactic 
administration of omeprazole would prevent development of oesophagitis in dogs that have su"ered transient 
vomiting or regurgitation. Routine use of omeprazole for treatment of acute, nonerosive gastritis in dogs is 
not recommended by a consensus panel, nor for prophylactic treatment of dogs with kidney disease that is not 
complicated by signs of gastrointestinal (GI)  disease4. For a number of conditions, there is currently insu#cient 
evidence to establish whether omeprazole produces a bene$cial e"ect in dogs; these include GI haemorrhage 
related to thrombocytopenia and liver disease without GI signs.
%e frequency of use of omeprazole in veterinary practice is unknown but, in human medicine, PPIs are 
among the most widely prescribed drugs, accounting for an estimated 113 million annual prescriptions in the 
 USA7. In humans, PPIs are associated with possible adverse  e"ects8, including bone fracture related to cal-
cium  malabsorption9, enteric bacterial  infections10, and de$ciencies of micronutrients such as vitamin  B1211. 
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Consequently, growing use of PPIs has been matched by concern about inappropriate prescriptions to patients 
who do not require them but could be exposed to their adverse  e"ects12. Of particular concern is hospital 
administration of PPIs, with previous studies showing that 30–60% of such prescriptions are inappropriate and 
that patients frequently continue to take PPIs beyond their hospital stay owing to failure of  deprescription13–16. 
In veterinary medicine, although the incidence of adverse e"ects attributable to GPs is unknown and probably 
lower than in people, guidelines have been advanced for their use based on clinical evidence and expert  opinion4. 
However, in our experience, PPIs are o&en used outside these recommendations in dogs, leading us to ask 
whether the rate of inappropriate prescriptions could be similar to that reported in people. If so, this practice 
could expose dogs to the risk of adverse e"ects, drug interactions, prescribing errors, and accidental overdoses, 
and also impose an unnecessary $nancial cost on their  owners17.
In addition to GPs, many dogs receive antiemetic treatment with the drug maropitant citrate, which acts as 
an antagonist for the neurokinin-1 receptor, inhibiting the actions of substance P and other tachykinins that may 
induce emesis. Maropitant, which is similar to aprepitant and fosaprepitant used in people, has been licensed for 
treatment of vomiting in dogs in the  UK18, 19. Previous studies have con$rmed it e"ectively reduces the occurrence 
of vomiting caused by  chemotherapy20, 21,  morphine22, and motion sickness in  dogs23, but its e"ect on nausea has 
been more di#cult to examine, partly owing to the notorious di#culty in evaluating this problem in  animals24. 
In previous investigations, maropitant had no e"ect on the frequency of nausea-associated behaviours, such as 
ptyalism, lip-licking, and swallowing, in dogs receiving  morphine22 or undergoing general  anaesthesia25, and 
was less e"ective for this purpose than the  5HT3 receptor antagonist  ondansetron26. Nevertheless, it has been 
our impression that maropitant is administered frequently in veterinary hospitals for treatment of vomiting and 
perceived nausea, leading us to ask, as with PPIs, whether this treatment was appropriate in all cases.
In this study, we sought to investigate (1) how frequently GPs and antiemetic drugs were administered to dogs 
presented with or without signs of GI disease, (2) what were the indications and risk factors for administration of 
omeprazole and maropitant in dogs, particularly when this was initiated in cases not presented for treatment of 
GI disease, (3) whether prescriptions of omeprazole and maropitant were appropriate when considered against 
published recommendations for their use, and (4) whether major patterns of and reasons for use di"ered between 
Medicine and Surgery wards of a veterinary hospital.
Results
population characteristics.  To investigate the use of GP and antiemetic drugs in veterinary specialist care, 
we conducted a prospective observational study in the Medicine and Surgery wards of our hospital. Data relating 
to administration of these drugs and observations on the clinical course of the patient were recorded for all dogs 
hospitalised for at least 24 h. In the periods of data collection, there were 261 eligible admissions to the Medicine 
ward and 146 to the Surgery ward. Among these, 24 admissions were excluded from further analysis because 
they represented repeated visits of dogs presented previously in the study period (22 in Medicine ward and 2 in 
Surgery ward). %e reasons for presentation of dogs in both wards are shown in Supplementary Table S1.
Among admitted cases, 96 dogs in Medicine ward (n = 239, 40.2%, 95% con$dence interval [CI]: 34.2–46.5) 
and 61 dogs in Surgery ward (n = 144, 42.4%, 95% CI: 34.6–50.5) received at least one dose of a GP drug (com-
prising omeprazole, sucralfate, ranitidine, or misoprostol), with no di"erence in proportion between wards 
(Chi squared 0.179, p = 0.672) (Fig. 1a). Similarly, there was no di"erence in the proportion of dogs in each 
ward receiving an antiemetic drug (comprising maropitant, ondansetron, or metoclopramide; Medicine: 96/239, 
40.2%, 95% CI: 34.2–46.5; Surgery 56/144, 38.9%, 95% CI: 31.3–47.0; Chi squared 0.06, p = 0.804) (Fig. 1b). %e 
frequency of administration of individual drugs in each ward is shown in Tables 1 and 2. Owing to the frequency 
of their use, we focused the remainder of our analysis on omeprazole and maropitant, though we present data 
relating to use of ondansetron in Supplementary Table S2.
ơ-
erinarians.  %e most commonly prescribed GP drug in both wards was omeprazole, which was usually 
administered intravenously (133/156 dogs, 85.3%) and twice daily (145/156 dogs, 92.9%) at a median dosage of 
2 mg/kg per day (inter-quartile range [IQR]: 2–2). In many cases in both wards, omeprazole was prescribed to 
dogs that were presented to the hospital with some combination of vomiting, regurgitation, or melaena, even if 
this was not the primary reason for referral. %is occurrence was more common in Medicine than Surgery ward 
(Medicine 56/96, 58.3%; Surgery 22/61, 36.1%; Chi squared 7.398, p = 0.007) (Fig. 1c), which probably re!ects 
the di"erence in caseload between these clinical disciplines.
Because we were surprised by the frequency of its use in hospitalised dogs, we enquired among clinicians 
about their general attitudes towards the use of omeprazole. Most considered it a safe or very safe drug (median 
score 2, IQR: 2–3, on a scale of -3 “very unsafe” to + 3 “very safe”, n = 14), but 7/14 (50%) believed incorrectly 
that it has a marketing authorisation for dogs in the UK. As a further possible factor that might a"ect its wide-
spread use, we asked clinicians to estimate the cost of administering omeprazole for 1 day to a 10 kg dog. In their 
responses, most (9/14, 64.3%) underestimated the true cost of £15.64. Collectively, this showed omeprazole is 
prescribed widely by clinicians who have few concerns about its safety and who underestimate its cost.
in hospitalised dogs presented without Gi signs, omeprazole is predominantly administered 
in response to new signs.  We wished to understand why omeprazole was being prescribed to hospitalised 
dogs that had not been presented with GI signs that might prompt its use. To investigate this, we asked clinicians 
to complete a questionnaire stating their indications for administration of omeprazole in each dog. Importantly, 
clinicians were prompted to complete the questionnaire in their own words within 1 week of prescribing the 
drug, meaning the information provided was contemporaneous to the clinical decision. %e response rate to 
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these questionnaires was good, with no di"erence between wards (Medicine 28 responses/40 dogs that received 
omeprazole without a prior history of vomiting, regurgitation, or melaena, 70.0%; Surgery 24/39, 61.5%, Chi 
squared 0.629, p = 0.428). We coded the responses from questionnaires into similar domains because some 
respondents provided multiple reasons for use of omeprazole; here, we report the frequency of these di"erent 
domains.
Stated indications for use of omeprazole by clinicians are shown in Table 3. In both wards, occurrence of 
vomiting and regurgitation while dogs were hospitalised was the most frequent indication when combined. 
Among Medicine clinicians, presence of a concurrent disease was noted as a contributory factor, consisting 
of azotaemia (n = 3), liver disease (1), pancreatitis (1), and in!ammatory bowel disease (1). Additionally, a 
Figure 1.  Gastroprotectants and antiemetics are administered frequently but with no di"erence between wards. 
Number of dogs receiving gastroprotectant (GP) drugs (a) or anti-emetics (AE) (b) during hospitalisation. 
Also shown are number of dogs presented without signs of gastrointestinal disease that received omeprazole or 
maropitant citrate (c).
Table 1.  Frequency of use of gastroprotectant drugs in hospitalised dogs.
Drug
Ward
Medicine (n = 239)
N (%)
Surgery (n = 144)
N (%)
Omeprazole 96 (40.2) 61 (42.4)
Ranitidine 1 (0.4) 0
Sucralfate 8 (3.3) 3 (2.1)
Misoprostol 3 (1.3) 0
Table 2.  Frequency of use of antiemetic drugs in hospitalised dogs.
Drug
Ward
Medicine (n = 239)
N (%)
Surgery (n = 144)
N (%)
Maropitant citrate 89 (37.2) 52 (36.1)
Ondansetron 41 (17.2) 1 (0.7)
Metoclopramide 9 (3.8) 12 (8.3)
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small proportion (14.3%) of respondents from the Medicine ward reported decreased appetite as a reason for 
administering omeprazole. In the Surgery ward, prophylactic treatment aiming to prevent GOR under general 
anaesthesia was frequently recorded as a reason for administering omeprazole, particularly for brachycephalic 
dogs undergoing surgery of the upper respiratory tract (37.5%).
Because questionnaire responses could be subject to bias owing to observer e"ects and inaccurate recollec-
tion, we wished to triangulate our results with objective data collected by nursing sta" from the same dogs while 
they were hospitalised. To do so, we constructed logistic regression models evaluating the association between 
ward observations, such as occurrence of GI signs, changes in appetite, and behavioural signs, with the decision 
to administer omeprazole during the hospital stay (Supplementary Table S3–S5). We produced separate models 
for Medicine and Surgery wards owing to the di"erences in the frequency of some potential risk factors, such 
as general anaesthesia.
In the medicine ward, length of hospitalisation and occurrence of vomiting or regurgitation (before omepra-
zole was administered) were independently associated with administration of omeprazole (Fig. 2a); the interac-
tion term for these variables was not signi$cant. Examining these associations in more detail, we found that 
although vomiting/regurgitation in hospitalised dogs was not common, occurring in 12/161 dogs not admitted 
for GI disease, most of those a"ected went on to receive omeprazole (9/12, 75.0%) (Fig. 2b). Although length of 
hospitalisation was associated with omeprazole administration, the majority of dogs began to receive it within 
1–2 days of admission (Fig. 2c). %is suggests administration of omeprazole identi$es those dogs destined to 
have a longer period of hospitalisation (Fig. 2d), rather than increasing as a function of hospitalisation.
Conducting the same analysis for dogs in the Surgery ward, we also found that vomiting or regurgitation 
increased the odds of omeprazole administration (Fig. 3a), with 10/14 (71.4%) dogs showing these signs going 
on to receive omeprazole a&er the episode (Fig. 3b). Additionally, we found dogs belonging to brachycephalic 
breeds were signi$cantly more likely to receive omeprazole, regardless of their reason for presentation (Fig. 3c). 
Speci$cally, 17/22 (77.3%) brachycephalic dogs received omeprazole in the Surgery ward, compared to 5/11 
(45.5%) of those in Medicine ward. Collectively, these models revealed striking concordance between indications 
stated by clinicians at the time of their clinical decision and objective data gathered in the wards: both modalities 
indicated the chief reason for administration of omeprazole in dogs presented without GI signs was for treatment 
of acute, hospital-acquired vomiting and/or regurgitation.
omeprazole  is  frequently  administered  outside  dosing  recommendations  and  for  reasons 
ơǤ Using recently published guidelines for the use of GP drugs in 
small animal practice that were based on the consensus recommendations of expert  clinicians4, 27, we wished to 
determine whether prescriptions for omeprazole were appropriate. Accordingly, we assessed each case accord-
ing to (1) drug factors, including the dosage and frequency of administration that should be achieved, and (2) 
patient factors, comprising indications stated by the clinician that were considered suitable for use of omeprazole 
(Table 4). Using these criteria, we found omeprazole was more commonly administered outside dosing recom-
mendations in the Surgery ward than the Medicine ward (Surgery 13/59, 22.0%; Medicine 4/95, 4.2%; Fisher’s 
exact test, p = 0.005), which was almost equally attributable to administration of doses outside the recommended 
range by > 10% or to once daily administration for two or more days (Table 5). However, when evaluating patient 
factors, there was no di"erence between wards in the proportion of cases where omeprazole was administered 
for a reason unrelated to its expected e"ects (Medicine 27/63, 42.9%; Surgery 12/38, 31.6%, Chi squared 6.95, 
p = 0.139). Taken together, this indicated the manner of or stated reasons for administering omeprazole did not 
meet recommendations in a considerable proportion of cases in both wards, but the reasons for this di"ered 
between them. 
As a $nal means to determine why clinicians in the Medicine ward might be administering omeprazole for 
the stated reason of decreased appetite, we provided two di"erent case scenarios of dogs with this problem. %e 
Table 3.  Stated indications for administration of omeprazole in dogs with no history of GI signs on 
presentation. GA: general anaesthesia; BOAS: brachycephalic airway obstructive syndrome. Note that numbers 
summate to more than the number of questionnaire responses because some questionnaires contained 
multiple domains.
Indication
Ward
Medicine (N = 28)
N (%)
Surgery (N = 24)
N (%)
Vomiting while hospitalised 7 (25.0) 3 (12.5)
Regurgitation while hospitalised 4 (14.3) 9 (37.5)
Diarrhoea while hospitalised 0 2 (8.3)
Decreased appetite while hospitalised 4 (14.3) 0
Signs of nausea while hospitalised 2 (7.1) 3 (12.5)
Signs of GI haemorrhage or ulceration 4 (14.3) 0
Concurrent disease 6 (21.4) 0
Concurrent medications 3 (10.7) 2 (8.3)
Prophylactic treatment to decrease risk of gastro-oesophageal re!ux 
under GA 0 10 (41.7), of which 9 (37.5) in dogs with BOAS
ͻVol.:(0123456789)
Scientific RepoRtS |        (2020) 10:15727  |  ǣȀȀǤȀͷͶǤͷͶ͹;ȀͺͷͻͿ;ǦͶ͸ͶǦͽ͸ͿͻͶǦ͹
www.nature.com/scientificreports/
$rst described a dog with decreased appetite while hospitalised for lower urinary tract (i.e. non-GI) disease, while 
the second described a dog with pancreatitis that did not have vomiting/regurgitation upon presentation but 
did have abdominal pain and decreased appetite (i.e. GI-related). Administration of omeprazole to either dog 
would be ‘inappropriate’ according to our patient factors. In response to these scenarios, no Medicine clinicians 
opted to administer omeprazole to the non-GI dog, but 2/9 (22.2%) chose to administer it to the GI-related case, 
both citing a possible risk of vomiting and oesophagitis but not indicating they expected it to increase appetite. 
%is suggested some willingness to implement treatment with omeprazole on a prophylactic basis, even in the 
absence of signs that it might be expected to a"ect.
Maropitant is administered frequently in hospitalised dogs.  In both wards, maropitant was usu-
ally administered intravenously (134/141, 95.0%) and at a dosage of 1 mg/kg once daily. When given orally 
(7/141 dogs), the median dosage was 1.9 mg/kg per day (IQR: 1.6–2.0). When asked about its administration, 
most respondents considered maropitant to be a safe or very safe drug (median score 2, IQR: 2–3, on a scale 
of − 3 to + 3, n = 14) and all correctly identi$ed that it had marketing authorisation in the UK. However, most 
respondents (11/14, 78.6%) also underestimated the cost of administering the drug for one day in a 10 kg dog, 
which was £18.32.
As with omeprazole, we found maropitant was o&en administered to dogs presented with signs of vomit-
ing, regurgitation, or nausea in both wards (Medicine 78/239, 32.6%; Surgery 28/144, 19.4%, Chi squared 7.81, 
p = 0.005). Examining those cases receiving maropitant without a history of such signs, the most common 
indications stated by clinicians in questionnaires are shown in Table 6. Among the concurrent diseases caus-
ing administration in Medicine ward were pancreatitis (n = 3) and azotaemia (1), compared to BOAS (n = 9) or 
vestibular syndrome/nystagmus (2) in Surgery. We again evaluated objective risk factors for administration of 
maropitant in both wards among this cohort of patients (Supplementary Tables S6–S8), $nding that duration of 
hospitalisation and decreased appetite while hospitalised were signi$cant predictors in a multivariable model 
for Medicine ward (Fig. 4a). As before, most dogs received maropitant early in their hospital stay (Fig. 4b), sug-
gesting it acted as a marker of longer hospitalisation (Fig. 4c). %e majority of dogs (20/33, 60.6%) observed to 
Figure 2.  Development of vomiting or regurgitation is the major predictor of omeprazole administration in 
Medicine ward. (a) Forest plot showing odds ratios and 95% con$dence intervals (CI) for variables signi$cantly 
associated with omeprazole administration in multivariable binary logistic regression analysis. Vomit/regurg: 
vomiting or regurgitation. Dashed line indicates threshold. (b) Violin plot showing duration of hospitalisation 
in dogs that did or did not receive omeprazole. Solid red lines indicate median; dashed red lines indicates 1st 
and 3rd quartiles. Groups compared by Mann–Whitney U test. (c) Kaplan–Meier plot showing duration of time 
to onset of omeprazole administration in those dogs that received it (n = 39). (d) Proportion of dogs that had 
vomiting or regurgitation among those that did or did not receive omeprazole. Bars show proportion with 95% 
con$dence intervals; groups compared by Chi squared test.
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have a decreased appetite while hospitalised received maropitant at some point during their stay (Fig. 4d). In the 
Surgery ward (Fig. 5a), decreased appetite was also signi$cantly associated with administration of maropitant 
(Fig. 5b), as was membership of a brachycephalic breed (Fig. 5c). %ese results demonstrated again that objective 
measures e"ectively recapitulated indications stated by clinicians for administration of maropitant, con$rming 
this was chie!y related to decreased appetite/presence of nausea and, in Surgery ward, to concern about regur-
gitation and/or GOR in brachycephalic dogs.
Maropitant is almost always administered as recommended but often for indications incom-
ơǤ Evaluating the drug and patient factors associated with administration 
of maropitant, we found it was almost always administered according to its marketing authorisation, with only 
2 dogs receiving a dosage > 10% below and 1 dog > 10% above the recommended amount (Table 7). However, in 
the Surgery ward, a considerable proportion (15/28, 53.6%) of dogs received maropitant for the stated reason 
of treating or preventing regurgitation, which was not considered compatible with its known e"ects, and the 
same indication was stated occasionally in the Medicine ward (n = 2). Collectively, this showed that maropitant 
was almost always administered correctly but was o&en being used with the intention of treating or preventing 
regurgitation, for which purpose it is also not licensed in the UK.
To investigate the attitudes underlying these decisions, we provided a case scenario to Surgery clinicians 
describing a dog with brachycephalic airway obstructive syndrome (BOAS) with intermittent regurgitation 
and ptyalism that is about to undergo surgery. In most cases (4/5), Surgery clinicians opted to administer both 
omeprazole and maropitant, with 1/5 choosing to administer omeprazole alone. Respondents could be split 
into those who indicated they believed this combination would decrease the risk of regurgitation during or a&er 
general anaesthesia (n = 3), and those who considered omeprazole would decrease the frequency or consequences 
of regurgitation while maropitant would alleviate nausea (n = 1), which was assumed to contribute to the GI 
signs. Taken together, this suggested there was a prevalent assumption among this group that maropitant would 
prevent regurgitation and/or nausea when published evidence does not support this notion.
Figure 3.  Membership of a brachycephalic breed and development of vomiting or regurgitation predict 
administration of omeprazole in Surgery ward. (a) Forest plot showing odds ratios and 95% con$dence intervals 
(CI) for variables signi$cantly associated with omeprazole administration in multivariable binary logistic 
regression analysis. Vomit/regurg: vomiting or regurgitation. Dashed line indicates threshold. (b) Proportion 
of dogs that had vomiting or regurgitation among those that did or did not receive omeprazole. Bars show 
proportion with 95% con$dence intervals; groups compared by Chi squared test. (c) Proportion of dogs 
belonging to a brachycephalic breed among those that did or did not receive omeprazole. Bars show proportion 
with 95% con$dence intervals; groups compared by Chi squared test.
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Discussion
Our study represents the $rst comprehensive investigation of the use of omeprazole and maropitant citrate in 
a veterinary hospital. We $nd that the most common drugs, omeprazole and maropitant, are administered to a 
large proportion of all admissions to our Medicine and Surgery wards, including to a considerable number of dogs 
that did not have GI signs before their presentation. %e stated indications and risk factors for administration of 
each drug di"er, but we $nd that development of GI signs while hospitalised is the major explanatory factor for 
use of omeprazole in such dogs. Assessing the use and stated indications for both drugs according to published 
materials, we $nd omeprazole is o&en administered outside its marketing authorisation, and that both drugs are 
frequently administered for purposes incompatible with their known e"ects in dogs.
%e incidence and consequences of adverse e"ects associated with use of omeprazole and maropitant are 
unknown in veterinary medicine, but overprescribing of any drug increases the risk of prescribing errors and acci-
dental overdoses, as well as imposing an unnecessary $nancial cost on the owners of the dog. Overprescribing of 
GP drugs is reported widely in human medicine, with known risk factors including incorrect diagnoses, overuse 
Table 4.  Drug and patient factors evaluated for inappropriate use of omeprazole and maropitant in dogs. *Not 
considered inappropriate owing to insu#cient published evidence on its use in this setting.
Drug factors Considered inappropriate
Omeprazole
Route IV or PO No
Frequency BID No
Dosage 1 mg/kg per dose, with margin of 10% above or below No
Drug interactions Concurrent administration with azole antifungal Yes
Maropitant
Route IV or PO No
Frequency SID No
Dosage 1 mg/kg per dose if IV or 2 mg/kg if PO, with margin of 10% above or below No
Patient factors
Omeprazole Indication
Vomiting if:
 Less than 3-week duration
 No evidence of haematemesis, melaena, or haemorrhage on endoscopy
 No concurrent regurgitation
 No evidence of ulceration on imaging
Yes
Chronic vomiting, or vomiting with regurgitation No
Regurgitation with risk of oesophagitis No
Gastro-oesophageal re!ux under GA No
Prophylactic administration before GA if reason to prevent gastro-oesophageal re!ux No
Evidence of gastroduodenal ulceration or erosion (e.g. ulcer observed by endoscopy or imaging, haematemesis, 
melaena) No
Symptomatic hepatic disease* No
IRIS stage 1–3 chronic kidney disease without GI signs Yes
IRIS stage 1–3 chronic kidney disease with vomiting, regurgitation, or GI bleeding* No
IRIS stage 4 chronic kidney disease, with or without GI signs* No
Pancreatitis without evidence of gastroduodenal ulceration Yes
GI bleeding with thrombocytopenia* No
Anorexia or decreased appetite Yes
Administration of glucocorticoids at immunosuppressive dosage without GI signs or evidence of ulceration Yes
Administration of non-steroidal anti-in!ammatory drugs in the absence of GI signs Yes
Diarrhoea without melaena or occult blood Yes
Indication not known Yes
Stated indication ‘continued from referring vet’ Yes
Signs of nausea Yes
Maropitant Indications
Vomiting No
Signs of nausea No
Diarrhoea Yes
Gastro-oesophageal re!ux under GA Yes
Prophylactic administration before GA if reason to anticipate gastro-oesophageal re!ux Yes
Anorexia/decreased appetite No
Indication not known Yes
Stated indication ‘continued from referring vet’ Yes
Regurgitation in the absence of vomiting Yes
Pancreatitis in the absence of vomiting, nausea, or decreased appetite Yes
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of PPIs for stress ulcer prophylaxis, and failure of deprescription in patients no longer needing  treatment12. %e 
occurrence of overprescribing and polypharmacy in veterinary medicine have rarely been investigated, but we 
suspect these practices are more likely to occur with drugs that are widely considered safe and a"ordable, as were 
omeprazole and maropitant among clinicians participating in this study. We believe this is likely to be a factor 
explaining the surprising rate of prescriptions, even among dogs not presented with any GI signs.
We identi$ed that omeprazole was o&en administered to dogs with vomiting that had no complicating fea-
tures, such as GI haemorrhage, ulceration, concurrent regurgitation, gastric mass lesions, or chronic signs that 
might indicate hypergastrinaemia. %is was also the major reason why omeprazole was administered in hospi-
talised dogs that were not presented with GI signs. In some cases, this could have been intended as prophylaxis 
against the development of oesophagitis, but this complication appears to be rare when set against the high inci-
dence of intermittent acute vomiting in  dogs28, 29. Furthermore, it is not proven in such cases that administration 
of omeprazole would prevent oesophagitis. Consequently, guidelines in veterinary medicine recommend against 
routine administration of PPIs for cases with uncomplicated  gastritis4, particularly because omeprazole causes 
considerable perturbation of the GI microbiome in  dogs30 and  people31. In cases where omeprazole is adminis-
tered for suppression of gastric acid production, previous work indicates twice daily administration is probably 
necessary for a reliable and durable  e"ect32. However, we found omeprazole was frequently being administered 
once daily, which was the recommendation published in older texts and formularies.
Maropitant was used most o&en for a stated indication of vomiting, which was considered appropriate for its 
known biological e"ects in dogs. However, it was also used frequently for nausea and decreased appetite, upon 
which signs it may have little e"ect depending on their origins. Although nausea is di#cult to detect in dogs, 
Table 5.  Frequency of drug and patient factors for inappropriate use of omeprazole. NSAID: non-steroidal 
anti-in!ammatory drug.
Factor
Ward
Medicine
N with inappropriate use (%)
Surgery
N with inappropriate use (%)
N = 95 N = 59
Drug factors 4 (4.2) 13 (22.0)
Dose 2 (2.1) 6 (10.2)
Frequency 2 (2.1) 7 (11.9)
Route 0 0
N = 63 N = 38
Patient factors 27 (42.9) 12 (31.6)
Diarrhoea 1 (1.6) 2 (5.3)
Decreased appetite 9 (14.3) 1 (2.6)
Continued from referring veterinarian 2 (3.2) 0
Vomiting unlikely to be responsive to omeprazole 10 (15.9) 2 (5.3)
Nausea 2 (3.2) 5 (13.2)
Immunosuppressive treatment 3 (4.8) 0
NSAID treatment 0 2 (5.3)
Table 6.  Stated indications for administration of maropitant in dogs with no history of GI signs on 
presentation. GA: general anaesthesia, BOAS: brachycephalic airway obstructive syndrome. Note that numbers 
summate to more than the number of questionnaire responses because some questionnaires contained 
multiple domains.
Indication
Ward
Medicine (N = 21)
N (%)
Surgery (N = 19)
N (%)
Vomiting while hospitalised 3 (14.3) 3 (15.8)
Regurgitation while hospitalised 1 (4.8) 5 (26.3)
Diarrhoea while hospitalised 0 0
Decreased appetite while hospitalised 10 (47.6) 2 (10.5)
Signs of nausea while hospitalised 9 (42.9) 6 (31.6)
Signs of GI haemorrhage or ulceration 0 0
Concurrent disease 4 (19.0) 11 (57.9)
Concurrent medications 0 0
Prophylactic treatment to decrease risk of gastro-oesophageal re!ux under GA 0 7 (36.8), all for dogs with BOAS
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previous studies have shown maropitant was not e"ective in decreasing nausea-associated behaviours a&er gen-
eral  anaesthesia25 or morphine  premedication22, though it did decrease them less e"ectively than ondansetron 
a&er cisplatin  treatment26. Of greater concern was the widespread use of maropitant for the stated indication of 
treating or preventing regurgitation. Maropitant is not licensed for this purpose in dogs, nor was it e"ective in 
preventing GOR in anaesthetised dogs when administered pre-operatively in a previous  study33.
We did not intend to investigate the management of brachycephalic dogs with BOAS in this study, but dogs 
of such breeds were signi$cantly more likely to receive omeprazole and maropitant in the Surgery ward for the 
stated reasons of decreasing the rate and/or consequences of regurgitation and GOR under anaesthesia. Both 
problems are common in brachycephalic  dogs34, 35, though the prevalence of intra-operative GOR did not di"er 
between brachycephalic and control dogs in a previous  study36. Regurgitation in brachycephalic dogs is attributed 
principally to excessive negative pressure in the  thorax37, but it is unclear whether a"ected dogs also experience 
nausea. Interestingly, owners reported ptyalism, which is o&en taken as a sign of nausea, to be much less com-
mon in such dogs than  regurgitation34. Additionally, in our experience, brachycephalic dogs with regurgitation 
rarely have a decreased appetite, which might be expected if they were experiencing nausea. Evidence against 
the notion of nausea as a contributory factor is also provided by the $nding that treatment of BOAS by surgery 
in brachycephalic dogs was su#cient to alleviate the frequency of regurgitation in most, without any additional 
medical  treatment34.
We believe widespread use of omeprazole and maropitant in brachycephalic dogs has been related to a previ-
ous study that concluded “medical treatment of upper GI disorders [using omeprazole and the prokinetic cisap-
ride]… dramatically improves the prognosis following surgical treatment of brachycephalic obstructive airway 
disease”38: this conclusion has been repeated subsequently by  others39. However, this study was a prospective 
case series, meaning that such conclusions could not be drawn in the absence of a control group. Furthermore, 
the authors found most dogs had sustained improvement of their GI signs a&er medical treatment was stopped, 
suggesting correction of the BOAS was the more important factor in resolving GI signs. Against this background, 
we suggest there is little indication for administering maropitant for peri-operative or long-term management of 
regurgitation or GOR in dogs with BOAS, but randomised controlled trials evaluating its e"ects on nausea and 
GOR in this population would be welcomed. In contrast to maropitant, there is evidence in non-brachycephalic 
dogs undergoing orthopaedic surgery that omeprazole decreases the frequency of oesophageal low pH  events5, 
though a later study with esomeprazole did not con$rm this  e"ect6. Owing to this evidence, we considered 
Figure 4.  Duration of hospitalisation and decreased appetite predict administration of maropitant in Medicine 
ward. (a) Forest plot showing odds ratios and 95% con$dence intervals (CI) for variables signi$cantly associated 
with maropitant administration in multivariable binary logistic regression analysis. Dashed line indicates 
threshold. (b) Kaplan–Meier plot showing duration of time to onset of maropitant administration in those dogs 
that received it (n = 37). (c) Violin plot showing duration of hospitalisation in dogs that did or did not receive 
maropitant. Solid red lines indicate median; dashed red lines indicates 1st and 3rd quartiles. Groups compared 
by Mann–Whitney U test. (d) Proportion of dogs that had decreased appetite among those that did or did not 
receive maropitant. Bars show proportion with 95% con$dence intervals; groups compared by Chi squared test.
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prevention of GOR to be an appropriate indication for administration of omeprazole in our hospital, even though 
the cost: bene$t balance is undetermined for this intervention.
Although data were collected prospectively in this study, resulting in a very low rate of missing objective 
data in the case registry and high con$dence in its accuracy, the rate of completion of questionnaires was lower, 
which is a limitation for the study. Additionally, we would ideally have asked clinicians to complete a question-
naire at the moment when they decided to prescribe a GP or antiemetic drug. Instead, we allowed up to one 
week to send the questionnaire, which could have a"ected the accuracy of recall for clinicians in a busy clinic. 
Furthermore, since we assured clinicians of their anonymity, we do not know if some clinicians completed 
questionnaires more o&en than others, meaning the opinions of some clinicians could have exerted a stronger 
e"ect in the $nal results. However, we mitigated this risk by calibrating questionnaire responses against objective 
Figure 5.  Membership of a brachycephalic breed and decreased appetite predict administration of maropitant 
in Surgery ward. (a) Forest plot showing odds ratios and 95% con$dence intervals (CI) for variables signi$cantly 
associated with maropitant administration in multivariable binary logistic regression analysis. Dashed line 
indicates threshold. (b) Proportion of dogs that had decreased appetite among those that did or did not receive 
maropitant. Bars show proportion with 95% con$dence intervals; groups compared by Chi squared test. (c) 
Proportion of dogs belonging to a brachycephalic breed among those that did or did not receive maropitant. 
Bars show proportion with 95% con$dence intervals; groups compared by Chi squared test.
Table 7.  Frequency of drug and patient factors for inappropriate use of maropitant.
Factor
Ward
Medicine
N with inappropriate use (%)
Surgery
N with inappropriate use (%)
N = 88 N = 53
Drug factors 1 (1.1) 3 (5.7)
Dose 1 (1.1) 3 (5.7)
Frequency 0 0
Route 0 0
N = 49 N = 28
Patient factors 2 (4.1) 15 (53.6)
Regurgitation—treatment or prophylaxis 2 (4.1) 15 (53.6)
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data where possible, $nding excellent concordance between these modalities. Data were collected from the two 
wards at di"erent times, but were analysed only a&er data collection was completed in both wards, meaning 
that no results were discussed before the Surgery ward was recruited to the study. %e act of asking clinicians to 
state their indications for use of GPs and antiemetics could have altered their responses, producing an observer 
e"ect. While we considered this unavoidable to some extent, we took care to frame the study among clinicians 
as a non-judgemental exercise in clinical governance, of which the goal was to evaluate the hospital culture of 
prescribing rather than the actions of individuals. Owing to its setting in a single centre, it is not clear if the 
results of our study are applicable more widely in veterinary specialist care: further studies will be required to 
determine if patterns of prescribing are similar in other centres.
In conclusion, we $nd omeprazole and maropitant are used in a large proportion of all cases presented for 
veterinary specialist care by clinicians who considered them safe and who underestimated their $nancial cost. 
However, they were o&en used outside dosing recommendations and with stated aims that were unlikely to be 
achieved by the known biological e"ects of the drugs in dogs. %e extent of this prescribing warrants interven-
tions to reduce the rate of polypharmacy.
Methods
Study setting.  All data collection was conducted in the (internal) Medicine and Surgery wards of a veteri-
nary university teaching hospital, which only accepts referral cases from primary care veterinarians predomi-
nantly in the South-east of England. At any time, new cases are admitted by 2–4 residents in each ward, under the 
supervision of board-certi$ed specialist veterinarians. Both wards are sta"ed by permanent veterinary nurses 
registered with the Royal College of Veterinary Surgeons, most of whom have additional specialist quali$cations 
in their areas of responsibility.
Study design.  A prospective observational study was conducted, which consisted of the following sections 
described in further detail:
1. Prospective case registry for dogs hospitalised for > 24 h
2. Questionnaires administered contemporaneously to clinicians of dogs that received a GP or antiemetic drug 
during their hospitalisation
3. Synoptic cross-sectional questionnaire administered to all clinicians who had participated in Sect. 2
%e study protocol was approved by the Royal Veterinary College clinical ethical review board (URN SR2017-
1292). Human participants gave informed consent for participation in the study. All research was conducted in 
accordance with relevant guidelines and regulations at our institution. A copy of all questionnaires used in the 
study is shown in Supplementary Methods.
prospective case registry.  All dogs admitted to Medicine ward between 6th August and 19th December 
2018 (period of 19 weeks) and to Surgery ward between 15th July and 24th November 2019 (period of 19 weeks) 
were eligible for enrolment in the registry. %e study was restricted to patients hospitalised for more than 24 h. 
For dogs hospitalised more than once in the same ward during the study period, data from the second and sub-
sequent visits was not used in the analysis. A structured form was used to standardise primary data collection 
for each eligible dog. Four types of information were collected: unique hospitalisation number and signalment; 
clinical signs and procedures; drugs administered; and signs of stress or agitation. On the day of patient admis-
sion to the ward, each dog was assigned a form for data collection; these forms were maintained by the perma-
nent nursing sta". At the time of a scheduled handover between nursing shi&s in the a&ernoon, the forms were 
updated with clinical information for the preceding 24 h: this included occurrences of vomiting, haematemesis, 
melaena, haematochezia, diarrhoea, regurgitation, and anorexia/decreased appetite; procedures under general 
anaesthesia; administration of GP or antiemetic drugs, glucocorticoids, NSAIDs, and anticoagulants; and signs 
of stress, including barking or vocalisation, digging or jumping at front of kennel, aggressive behaviour, or with-
drawal/nervousness. In this way, information was recorded for each hospitalised dog prospectively on a daily 
basis during its hospital stay by sta" who were employed permanently in the same ward. %e forms were checked 
by the project co-ordinator for completeness every day, and missing information was obtained directly or by 
sending e-mails. Upon patient discharge, the forms were $led until analysis was completed.
contemporaneous questionnaires.  In every dog where a GP or antiemetic drug was administered in 
the hospital, the attending clinician was asked by the project co-ordinators by e-mail to complete a structured 
questionnaire within 1 week of the prescription. In this questionnaire, the clinician was asked to state the name, 
dosage, and dose frequency of the drugs being administered, the expected duration of the course, and their 
indications for administration. Importantly, clinicians were prompted to give their main indications for each 
drug separately and in their own words. %e questionnaire could be completed online (via a link in the e-mail) 
or on paper. At the outset of the study, clinicians were assured of their anonymity for these questionnaires, mean-
ing the study co-ordinators sent blanket reminder e-mails but were unable to follow up individual cases if not 
completed. Responses from these questionnaires were coded to relate similar terms together for description, e.g. 
“anorexia” and “inappetence” were placed in the same domain.
Synoptic questionnaire.  A&er all data collection was completed, all clinicians who participated in the 
preceding section were asked to complete a synoptic questionnaire containing questions about the general use 
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of omeprazole and maropitant, including their perception of the safety of the drugs, their cost, and their pos-
sible adverse e"ects. In addition, case scenarios were provided to try to resolve areas of interest in the initial data 
analysis.
Assessment of appropriate prescribing.  For the drugs omeprazole and maropitant, a list of drug fac-
tors (dosage, frequency, route of administration) and patient factors (appropriate reasons for use) was compiled, 
with reference to the marketing authorisation for maropitant and to published guidelines for GPs (shown in 
Table 4)4, 27. Assessment of drug factors was undertaken by reviewing the hospital ward sheets for every dog. 
Assessment of patient factors was undertaken primarily from the questionnaire responses provided by attending 
clinicians. Where a response was ambiguous, e.g. “vomiting” as an indication for omeprazole, the clinical record 
was reviewed by one study co-ordinator to determine if additional factors would render the decision appropriate 
according to the stated criteria. %is varied among cases but usually included review of the clinical history and 
results of imaging performed by board-certi$ed specialists in diagnostic imaging.
Statistical analysis.  All analyses were conducted with proprietary so&ware (SPSS version 24, IBM; Graph-
Pad Prism version 8, GraphPad So&ware Inc). Variables were assessed for normality by visual inspection of 
histograms and Kolmogorov–Smirnov tests. Since all pertinent variables were non-normally distributed, central 
tendency is described by median with IQR. Associations between categorical variables were assessed using Chi 
squared tests, or Fisher exact tests if there were fewer than 5 cases in any cell. Di"erences in continuous variables 
between groups were compared using Mann–Whitney U tests. Kaplan–Meier curves were produced to show 
when omeprazole and maropitant were administered in the hospital stay.
For assessment of risk factors for administration of omeprazole or maropitant in Medicine or Surgery wards, 
candidate variables were $rst assessed in univariable binary logistic regression. %ose variables associated with 
administration at p < 0.1 were considered in the multivariable model, which was constructed by stepwise back-
wards elimination of non-signi$cant variables based on calculation of the likelihood ratio. Interactions among 
variables in $nal models were evaluated by introducing the interaction term; this was discarded if not signi$cant. 
%e performance of models was evaluated by inspecting the receiver operator characteristic (ROC) curve and 
calculating the area under it, and by considering the proportion of cases correctly classi$ed by the model.
Depending on the question being asked, the number of dogs used in each part of the analysis di"ered and 
is explained below:
• Description of overall frequency of administration of GP and antiemetic drugs: all dogs.
• Reasons and risk factors for administration of omeprazole and maropitant in dogs not presented with GI 
signs: only those dogs that did not have vomiting, regurgitation, diarrhoea, melaena, or regurgitation among 
their presenting problems.
• Assessment of drug factors in prescriptions of omeprazole and maropitant: all dogs that received these drugs.
• Assessment of patient factors in prescriptions of omeprazole and maropitant: those dogs that received these 
drugs and where a clinician completed a questionnaire to indicate why they prescribed it.
Received: 22 July 2020; Accepted: 8 September 2020
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